| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/14/2002 | WO2002011677A2 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 02/14/2002 | WO2002011666A2 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 02/14/2002 | WO2002011665A2 Association of a purine and a nonsteroidal anti-inflammatory drug for treating sexual dysfunction |
| 02/14/2002 | WO2002011551A2 Oil/fat composition |
| 02/14/2002 | WO2002011550A2 Oil/fat composition |
| 02/14/2002 | WO2001081415A9 Parathyroid hormone and parathyroid hormone-related protein antagonists |
| 02/14/2002 | WO2001073018A3 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 02/14/2002 | WO2001072838A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/14/2002 | WO2001072264A3 Pro-liposomal encapsulated preparations (iv) |
| 02/14/2002 | WO2001068670A3 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof |
| 02/14/2002 | WO2001068603A3 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 02/14/2002 | WO2001064874A3 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/14/2002 | WO2001064247A3 Method of treating cancer with anti-neurotrophin agents |
| 02/14/2002 | WO2001064008A3 Vaccine for the treatment of artherosclerosis |
| 02/14/2002 | WO2001062954A8 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 02/14/2002 | WO2001059120A3 Il-17 like molecules and uses thereof |
| 02/14/2002 | WO2001058951A3 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 02/14/2002 | WO2001058915A3 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 02/14/2002 | WO2001057210A3 Use of dendroaspin as a vehicle for non-dendroaspin domains |
| 02/14/2002 | WO2001055092A3 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 02/14/2002 | WO2001054679A3 Transdermal composition containing an anesthetic and a vasodilator agent |
| 02/14/2002 | WO2001051619A3 Genetically modified fibroblast cell |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001041807A3 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 02/14/2002 | WO2001041750A3 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
| 02/14/2002 | WO2001037852A3 Methods of inhibiting atrophy or promoting hypertrophy |
| 02/14/2002 | WO2001034137A3 Oncolytic combinations for the treatment of cancer |
| 02/14/2002 | WO2001034134A3 Oncolytic combinations for the treatment of cancer |
| 02/14/2002 | WO2001034133A3 Oncolytic combinations for the treatment of cancer |
| 02/14/2002 | WO2001032695A3 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 02/14/2002 | WO2001021771A3 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 02/14/2002 | WO2000061188A9 Sodium channel blocker compositions and the use thereof |
| 02/14/2002 | WO2000009552A9 Secreted proteins and polynucleotides encoding them |
| 02/14/2002 | WO1995001170A3 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders |
| 02/14/2002 | US20020019992 Transgenic non-human mammals with progressive neurologic disease |
| 02/14/2002 | US20020019523 Dietetics; antidabetic agents; sexual disrders |
| 02/14/2002 | US20020019519 KIAA0551 polynucleotides and polypeptides use |
| 02/14/2002 | US20020019443 Therapeutic use of D-methionine to reduce the toxicity of noise |
| 02/14/2002 | US20020019425 Anticancer agents; administering p53 gene or protein |
| 02/14/2002 | US20020019415 Cancer treatment |
| 02/14/2002 | US20020019411 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 02/14/2002 | US20020019377 Combination therapy for inhibiting sphincter incontinence |
| 02/14/2002 | US20020019364 Compounds for the treatment of psychiatric or substance abuse disorders |
| 02/14/2002 | US20020019363 Viricides for hepatitis c |
| 02/14/2002 | US20020019360 Treatment for cardiovascular disease |
| 02/14/2002 | US20020019353 Single-dose administration |
| 02/14/2002 | US20020019351 Treatment of skeletal disorders |
| 02/14/2002 | US20020019345 Administering to a patient having implant an effective amount of antagonist of CCR5 (chemokine receptor 5) function, to inhibit graft rejection, antagonist selected from small organic molecules, peptides, proteins, peptidomimetics |
| 02/14/2002 | US20020019343 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol |
| 02/14/2002 | US20020019341 Modulation of systemic memory T cell trafficking |
| 02/14/2002 | US20020019028 Peptide; for use in the treatment of defects associated with polypeptide transfer |
| 02/14/2002 | US20020019016 Classifying nervous system disorders; obtain tissue, detect preferential tau protein in sample |
| 02/14/2002 | US20020019011 Mixture of therapeutic particles for use in the treatment of aging, viral, genetic and cancer diseases |
| 02/14/2002 | US20020019010 Treating aging, viral, genetic and cancer diseases in humans; provide therapeutic particles, generate layout, provide test sample, incubate with sample, monitor sample for reduction in injury associated with defect |
| 02/14/2002 | US20020018812 Sponge-like or foam |
| 02/14/2002 | US20020018804 Biological bioadhesive composition and methods of preparation and use |
| 02/14/2002 | US20020018782 Binding to antibodies; prophylaxis, therapy of infections |
| 02/14/2002 | US20020018776 Method of treating graft rejection using inhibitors of CXCR3 function |
| 02/14/2002 | US20020018773 Using lipase |
| 02/14/2002 | US20020018752 Ablation disease by cutting, blocking blood supply to tissue |
| 02/14/2002 | DE10036871A1 Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe Dispersions for the formulation of poorly soluble drugs or little |
| 02/14/2002 | DE10032296A1 Composition for cancer prophylaxis comprises substances that promote embryonic cell growth |
| 02/14/2002 | CA2634715A1 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl)oxy}-11.beta.-hydroxy-16.alpha-methyl-3-oxo-androsta-1,4-diene-17.beta.carbothioic acids-fluoromethyl ester as an anti-inflammatory agent |
| 02/14/2002 | CA2453907A1 Association of sim2 with cancer |
| 02/14/2002 | CA2420066A1 Use, in combination, of a purine activity and a nonsteroidal anti-inflammatory drug for preparing an anti-thrombotic and/or anti-inflammatory drug |
| 02/14/2002 | CA2419062A1 Methods for culturing human lung mast cells and uses thereof |
| 02/14/2002 | CA2419042A1 Medicine for fighting against sexual dysfunction |
| 02/14/2002 | CA2419036A1 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 02/14/2002 | CA2419027A1 Bicyclic compounds as h3 receptor ligands |
| 02/14/2002 | CA2418995A1 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/14/2002 | CA2418946A1 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 02/14/2002 | CA2418904A1 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2418386A1 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
| 02/14/2002 | CA2418369A1 Non-imidazole aryloxyalkylamines as h3 receptor ligands |
| 02/14/2002 | CA2418083A1 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 02/14/2002 | CA2418014A1 Immunotherapy for chronic myelocytic leukemia |
| 02/14/2002 | CA2417973A1 Formulations of mometasone and a bronchodilator for pulmonary administration |
| 02/14/2002 | CA2417826A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 02/14/2002 | CA2417769A1 Drug metabolizing enzymes |
| 02/14/2002 | CA2417755A1 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | CA2417676A1 Sequences for integrin alpha-8 |
| 02/14/2002 | CA2417606A1 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 02/14/2002 | CA2417604A1 Use of essential oils for combating gi tract infection by helicobacter-like organisms |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2417368A1 Suppressor gene |
| 02/14/2002 | CA2416767A1 Liquid formulation of metformin |
| 02/14/2002 | CA2416531A1 Compositions for preventing urinary calculus |
| 02/14/2002 | CA2406961A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 02/14/2002 | CA2386725A1 Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| 02/14/2002 | CA2386103A1 Vascular endothelial growth factor 2 |
| 02/13/2002 | EP1179541A1 Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| 02/13/2002 | EP1179353A1 Antithrombogenic implants with coating of polyphosphazenes and a pharmacologically active agent |
| 02/13/2002 | EP1179186A2 Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction |
| 02/13/2002 | EP1179182A2 Diagnosis and treatment of atherosclerosis and coronary heart disease |
| 02/13/2002 | EP1179094A2 Assay for the detection of paclitaxel resistant cells in human tumors |
| 02/13/2002 | EP1179093A1 Expression of ets-domain proteins in cancer |
| 02/13/2002 | EP1179086A2 Methods of identifying therapeutic compounds in a genetically defined setting |
| 02/13/2002 | EP1179067A1 Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily |
| 02/13/2002 | EP1179066A2 Extracellular signaling molecules |